Clinical or laboratory features predicting response to alemtuzumab
Clinical or laboratory feature . | No. CR or PR (%) . |
|---|---|
| Age, y | |
| Younger than 60, n = 17 | 5 (29) |
| 60 or older, n = 19 | 6 (32) |
| Rai stage | |
| Intermediate risk, n = 9 | 4 (44) |
| High risk, n = 27 | 7 (26) |
| Prior therapies | |
| 3 or less, n = 18 | 6 (33) |
| More than 3, n = 3 | 5 (28) |
| Fludarabine refractory | |
| Yes, n = 29 | 7 (24) |
| No, n = 7 | 4 (57) |
| Genetic prioritization* | |
| p53 mutation/del(17)(p13.1), n = 15 | 6 (40) |
| del(11)(q22.3)*, n = 11 | 3 (27) |
| Trisomy 12, n = 3 | 1 (33) |
| del(13)(q14), n = 4 | 1 (25) |
| Normal interphase cytogenetics, n = 3 | 0 (0) |
Clinical or laboratory feature . | No. CR or PR (%) . |
|---|---|
| Age, y | |
| Younger than 60, n = 17 | 5 (29) |
| 60 or older, n = 19 | 6 (32) |
| Rai stage | |
| Intermediate risk, n = 9 | 4 (44) |
| High risk, n = 27 | 7 (26) |
| Prior therapies | |
| 3 or less, n = 18 | 6 (33) |
| More than 3, n = 3 | 5 (28) |
| Fludarabine refractory | |
| Yes, n = 29 | 7 (24) |
| No, n = 7 | 4 (57) |
| Genetic prioritization* | |
| p53 mutation/del(17)(p13.1), n = 15 | 6 (40) |
| del(11)(q22.3)*, n = 11 | 3 (27) |
| Trisomy 12, n = 3 | 1 (33) |
| del(13)(q14), n = 4 | 1 (25) |
| Normal interphase cytogenetics, n = 3 | 0 (0) |
Prioritization was performed as follows: del(17)(p13.1) or p53 mutation > del(11)(q22.3) > trisomy 12 > del (13)(q14) > normal.